R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Scientist 1 - Biomarker Sciences, Translational Sciences

Quantitative Biology & BiostatisticsPosted on Nov 9
Full-timeRedwood City, CA, USA

About the Job

Requirements

  • A PhD in Cancer Biology, Molecular Oncology, Molecular Medicine, Human Genetics, or a related translational biomedical discipline, with 4+ years of relevant postdoctoral and/or industry experience in oncology drug discovery and development.
  • Substantial hands-on experience analyzing and biologically interpreting complex omics datasets, including bulk and single-cell sequencing, spatial transcriptomics, and integrated molecular, phenotypic, and clinical/translational data.
  • A strong background in oncology, cancer genomics, and translational biology, with the ability to independently frame biological questions and translate computational findings into testable hypotheses and drug-development insights.
  • Demonstrated experience and proficiency applying and evaluating machine learning and emerging AI-enabled approaches to biological data analysis.
  • Proficiency in R and/or Python for biological data analysis and interpretation, with a commitment to reproducible and rigorous analytical practices.
  • A strong foundation in statistical analysis and experimental design for high-dimensional biological and biomarker data.

Responsibilities

  • Apply computational approaches to uncover biomarkers, mechanisms of drug response and resistance, pharmacodynamic effects, and therapeutic strategies across translational studies.
  • Analyze and integrate bulk and single-cell sequencing, spatial transcriptomics, and other molecular data with biomarker, pathology, and efficacy/response outcomes to generate actionable biological hypotheses.
  • Develop reproducible analytical workflows and partner on AI-enabled solutions that accelerate exploratory data analysis, visualization, and biological interpretation.
  • Partner across Translational Research, Translational Medicine, Discovery, Bioinformatics, and Information Sciences to address scientific questions across the portfolio.
  • Analyze and integrate multimodal molecular and phenotypic datasets from translational studies to identify biomarkers, pharmacodynamic effects, mechanisms of response and resistance, and combination hypotheses.
  • Perform cross-study analyses to identify reproducible biological signals and translate computational findings into testable mechanistic and translational hypotheses.
  • Partner with experimental scientists on study design and testing of computationally derived biological hypotheses.
  • Partner with Biomarker Assays teams to translate insights into actionable biomarker analytes.
  • Partner with data science and technology teams to translate scientific needs into scalable analytical and visualization solutions.
  • Evaluate and apply emerging AI/ML approaches to accelerate analysis, data integration, and biological insight generation.
  • Communicate complex analyses and biological conclusions to multidisciplinary project teams and scientific leadership.

Desired Qualifications

  • Background in oncology drug discovery or development within a biotechnology or pharmaceutical environment.
  • Experience analyzing and interpreting longitudinal baseline, on-treatment, and resistance/progression datasets.
  • Ability to integrate sequencing data with proteomics, pathology, ctDNA, pharmacology, and/or clinical outcomes.
  • Familiarity with cloud-based analytical environments such as Databricks and collaboration on interactive analytical and visualization tools.
  • Knowledge of RAS/MAPK biology and RAS-driven cancers.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs